{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:44Z","timestamp":1791924224008,"version":"4.3.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11739-025-04050-x","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T07:45:46Z","timestamp":1752911146000},"page":"2479-2491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of acute kidney injury in tumor lysis syndrome: a narrative review"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-7947","authenticated-orcid":false,"given":"Laura","family":"Zeppilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-1602","authenticated-orcid":false,"given":"Santo","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-765X","authenticated-orcid":false,"given":"Antonietta","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-9462","authenticated-orcid":false,"given":"Valentina","family":"Pistolesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"4050_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","volume":"28","author":"T Barbar","year":"2021","unstructured":"Barbar T, Sathick IJ (2021) Tumor lysis syndrome. Adv Chronic Kidney Dis 28:438\u2013446. https:\/\/doi.org\/10.1053\/j.ackd.2021.09.007","journal-title":"Adv Chronic Kidney Dis"},{"key":"4050_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/joa3.12482","volume":"37","author":"K Gangani","year":"2020","unstructured":"Gangani K, Fong HE, Faisaluddin M et al (2020) Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: a nationwide inpatient analysis. J Arrhyth 37:121\u2013127. https:\/\/doi.org\/10.1002\/joa3.12482","journal-title":"J Arrhyth"},{"key":"4050_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","volume":"10","author":"SC Howard","year":"2024","unstructured":"Howard SC, Avagyan A, Workeneh B, Pui CH (2024) Tumour lysis syndrome. Nat Rev Dis Primers 10:58. https:\/\/doi.org\/10.1038\/s41572-024-00542-w","journal-title":"Nat Rev Dis Primers"},{"key":"4050_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-n","volume":"94","author":"KR Hande","year":"1993","unstructured":"Hande KR, Garrow GC (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin\u2019s lymphoma. Am J Med 94:133\u2013139. https:\/\/doi.org\/10.1016\/0002-9343(93)90174-n","journal-title":"Am J Med"},{"key":"4050_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"key":"4050_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"4050_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000538328","volume":"49","author":"N Alhamid","year":"2024","unstructured":"Alhamid N, Sabbagh B, Alsarraj A et al (2024) Pitfalls of current diagnostic criteria of tumor lysis syndrome. Kidney Blood Press Res 49:266\u2013272. https:\/\/doi.org\/10.1159\/000538328","journal-title":"Kidney Blood Press Res"},{"key":"4050_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.03140312","volume":"7","author":"AQ Lam","year":"2012","unstructured":"Lam AQ, Humphreys BD (2012) Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol 7:1692\u20131700. https:\/\/doi.org\/10.2215\/CJN.03140312","journal-title":"Clin J Am Soc Nephrol"},{"key":"4050_CR9","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767\u20132778. https:\/\/doi.org\/10.1200\/JCO.2007.15.0177","journal-title":"J Clin Oncol"},{"key":"4050_CR10","doi-asserted-by":"publisher","first-page":"390.e3","DOI":"10.1016\/j.ajem.2010.12.029","volume":"30","author":"A El-Husseini","year":"2012","unstructured":"El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A (2012) Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. Am J Emerg Med 30:390.e3\u20136. https:\/\/doi.org\/10.1016\/j.ajem.2010.12.029","journal-title":"Am J Emerg Med"},{"key":"4050_CR11","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","volume":"24","author":"M Shimada","year":"2009","unstructured":"Shimada M, Johnson RJ, May WS Jr et al (2009) A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transpl 24:2960\u20132964. https:\/\/doi.org\/10.1093\/ndt\/gfp330","journal-title":"Nephrol Dial Transpl"},{"key":"4050_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10157-004-0292-0","volume":"8","author":"RS Khan","year":"2004","unstructured":"Khan RS (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75\u201388. https:\/\/doi.org\/10.1007\/s10157-004-0292-0","journal-title":"Clin Exp Nephrol"},{"key":"4050_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bjh.16278","volume":"188","author":"U Durani","year":"2020","unstructured":"Durani U, Hogan WJ (2020) Emergencies in haematology: tumour lysis syndrome. Br J Haematol 188:494\u2013500. https:\/\/doi.org\/10.1111\/bjh.16278","journal-title":"Br J Haematol"},{"key":"4050_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/biomedicines10051012","volume":"10","author":"G Lupusoru","year":"2022","unstructured":"Lupusoru G, Ailinc\u0103i I, Fr\u0103til\u0103 G et al (2022) Tumor lysis syndrome: an endless challenge in onco-nephrology. Biomedicines 10:1012. https:\/\/doi.org\/10.3390\/biomedicines10051012","journal-title":"Biomedicines"},{"key":"4050_CR15","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1681\/ASN.2021070997","volume":"33","author":"M Arnaud","year":"2022","unstructured":"Arnaud M, Loiselle M, Vaganay C et al (2022) Tumor lysis syndrome and AKI: beyond crystal mechanisms. JASN 33:1154\u20131171. https:\/\/doi.org\/10.1681\/ASN.2021070997","journal-title":"JASN"},{"key":"4050_CR16","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.7759\/cureus.8355","volume":"12","author":"D Findakly","year":"2020","unstructured":"Findakly D, Luther RD, Wang J (2020) Tumor lysis syndrome in solid tumors: a comprehensive literature review, new insights, and novel strategies to improve outcomes. Cureus 12:e835. https:\/\/doi.org\/10.7759\/cureus.8355","journal-title":"Cureus"},{"key":"4050_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/01926230390224674","volume":"3","author":"K Lovelace","year":"2003","unstructured":"Lovelace K, vanGessel Y, Asher LV, Vogel P (2003) Spontaneous acute tumor lysis syndrome in a DBA\/1J mouse: a case report and review. Toxicol Pathol 3:486\u2013490. https:\/\/doi.org\/10.1080\/01926230390224674","journal-title":"Toxicol Pathol"},{"key":"4050_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s0002-9343(97)00153-8","volume":"103","author":"GP Kalemkerian","year":"1997","unstructured":"Kalemkerian GP, Darwish B, Varterasian ML (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103:363\u2013367. https:\/\/doi.org\/10.1016\/s0002-9343(97)00153-8","journal-title":"Am J Med"},{"key":"4050_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1042819021000054661","volume":"44","author":"L Annemans","year":"2003","unstructured":"Annemans L, Moeremans K, Lamotte M et al (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin\u2019s lymphoma in four European countries. Leuk Lymphoma 44:77\u201383. https:\/\/doi.org\/10.1080\/1042819021000054661","journal-title":"Leuk Lymphoma"},{"key":"4050_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00000421-199412000-00010","volume":"17","author":"P Drakos","year":"1994","unstructured":"Drakos P, Bar-Ziv J, Catane R (1994) Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 17:502\u2013505. https:\/\/doi.org\/10.1097\/00000421-199412000-00010","journal-title":"Am J Clin Oncol"},{"key":"4050_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1634\/theoncologist.2017-0147","volume":"22","author":"U Durani","year":"2017","unstructured":"Durani U, Shah ND, Go RS (2017) In-Hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample. Oncologist 22:1506\u20131509. https:\/\/doi.org\/10.1634\/theoncologist.2017-0147","journal-title":"Oncologist"},{"key":"4050_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.htct.2023.02.005","volume":"46","author":"ET Calvache","year":"2024","unstructured":"Calvache ET, Calvache ADT, Weber CS (2024) Tumor lysis syndrome in hematological inpatients, experience from a university hospital in Brazil: a retrospective cohort study. Hematol Transfus Cell Ther 46:340\u2013344. https:\/\/doi.org\/10.1016\/j.htct.2023.02.005","journal-title":"Hematol Transfus Cell Ther"},{"key":"4050_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","volume":"120","author":"MS Cairo","year":"2012","unstructured":"Cairo MS, Thompson S, Stern L, Sherman S (2012) Incidence of treatment-related, laboratory and clinical tumor lysis syndrome. Blood 120:238. https:\/\/doi.org\/10.1182\/blood.V120.21.238.238","journal-title":"Blood"},{"key":"4050_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000534453","volume":"147","author":"FA Rios-Olais","year":"2024","unstructured":"Rios-Olais FA, Gil-L\u00f3pez F, Mora-Ca\u00f1as A, Demichelis-G\u00f3mez R (2024) Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia. Acta Haematol 147:391\u2013401. https:\/\/doi.org\/10.1159\/000534453","journal-title":"Acta Haematol"},{"key":"4050_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","volume":"95","author":"SC Howard","year":"2016","unstructured":"Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563\u2013573. https:\/\/doi.org\/10.1007\/s00277-015-2585-7","journal-title":"Ann Hematol"},{"key":"4050_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40261-023-01308-0","volume":"43","author":"S Xia","year":"2023","unstructured":"Xia S, Ma JT, Raschi E et al (2023) Tumor lysis syndrome with CD20 monoclonal antibodies for chronic lymphocytic leukemia: signals from the FDA adverse event reporting system. Clin Drug Investig 43:773\u2013783. https:\/\/doi.org\/10.1007\/s40261-023-01308-0","journal-title":"Clin Drug Investig"},{"key":"4050_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","volume":"62","author":"H Yang","year":"1999","unstructured":"Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247\u2013250. https:\/\/doi.org\/10.1002\/(SICI)1096-8652(199912)62:4%3c247::AID-AJH9%3e3.0.CO;2-T","journal-title":"Am J Hematol"},{"key":"4050_CR28","doi-asserted-by":"publisher","unstructured":"Li D, Qin C, Wang H, et al (2024) Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA adverse event reporting system database. Ther Adv Drug Saf 15. https:\/\/doi.org\/10.1177\/20420986241274909","DOI":"10.1177\/20420986241274909"},{"key":"4050_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3816\/CLM.2006.n.064","volume":"7","author":"O Sezer","year":"2006","unstructured":"Sezer O, Vesole DH, Singhal S et al (2006) Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 7:233\u2013235. https:\/\/doi.org\/10.3816\/CLM.2006.n.064","journal-title":"Clin Lymphoma Myeloma"},{"key":"4050_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1186\/s12885-020-07592-9","volume":"20","author":"M Kondo","year":"2020","unstructured":"Kondo M, Hotta Y, Yamauchi K et al (2020) Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study. BMC Cancer 20:1117. https:\/\/doi.org\/10.1186\/s12885-020-07592-9","journal-title":"BMC Cancer"},{"key":"4050_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","volume":"100","author":"F Bouclet","year":"2021","unstructured":"Bouclet F, Calleja A, Dilhuydy MS et al (2021) Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol 100:987\u2013993. https:\/\/doi.org\/10.1007\/s00277-021-04419-w","journal-title":"Ann Hematol"},{"key":"4050_CR32","doi-asserted-by":"publisher","first-page":"sfae359","DOI":"10.1093\/ckj\/sfae359","volume":"18","author":"M Kanbay","year":"2025","unstructured":"Kanbay M, Mizrak B, Alper EN, Copur S, Ortiz A (2025) Acute kidney injury following CAR-T cell therapy: a nephrologist\u2019s perspective. Clin Kidney J 18:sfae359. https:\/\/doi.org\/10.1093\/ckj\/sfae359","journal-title":"Clin Kidney J"},{"key":"4050_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctro.2021.11.004","volume":"12","author":"A Cailleteau","year":"2021","unstructured":"Cailleteau A, Touzeau C, Jamet B, Guimas V, Jouglar E, Supiot S (2021) Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: a case report and review of the literature. Clin Transl Radiat Oncol 12:24\u201328. https:\/\/doi.org\/10.1016\/j.ctro.2021.11.004","journal-title":"Clin Transl Radiat Oncol"},{"key":"4050_CR34","doi-asserted-by":"publisher","unstructured":"Kawamoto T, Karino T, Muramoto Y, Oshima M, Kosugi Y, Shikama N (2023) Palliative radiotherapy induced severe tumor lysis syndrome in a patient with multiple myeloma with skin involvement: a case report and review of literature. Cancer Diagn Progn 3:257\u2013263. https:\/\/doi.org\/10.21873\/cdp.10210","DOI":"10.21873\/cdp.10210"},{"key":"4050_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40792-024-01901-1","volume":"10","author":"M Kikuchi","year":"2024","unstructured":"Kikuchi M, Miyabe R, Matsushima H et al (2024) Tumor lysis syndrome following letrozole for locally advanced breast cancer: a case report. Surg Case Rep 10:100. https:\/\/doi.org\/10.1186\/s40792-024-01901-1","journal-title":"Surg Case Rep"},{"key":"4050_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.2830470212","volume":"47","author":"AM Jasek","year":"1994","unstructured":"Jasek AM, Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47:129\u2013131. https:\/\/doi.org\/10.1002\/ajh.2830470212","journal-title":"Am J Hematol"},{"key":"4050_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/BF02983533","volume":"79","author":"HH Hsu","year":"2004","unstructured":"Hsu HH, Huang CC (2004) Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol 79:48\u201351. https:\/\/doi.org\/10.1007\/BF02983533","journal-title":"Int J Hematol"},{"key":"4050_CR38","doi-asserted-by":"publisher","first-page":"242.e1","DOI":"10.1016\/j.ajem.2023.11.010","volume":"78","author":"A Gartenberg","year":"2024","unstructured":"Gartenberg A, Winkel M, Leonard N (2024) Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol. Am J Emerg Med 78:242.e1-242.e3. https:\/\/doi.org\/10.1016\/j.ajem.2023.11.010","journal-title":"Am J Emerg Med"},{"key":"4050_CR39","doi-asserted-by":"publisher","unstructured":"Gusdorf J, Markovitz NH, Ricketts C, et al (2024) Spontaneous tumor lysis syndrome secondary to metastatic pancreatic adenocarcinoma. ACG Case Rep J 11:e01305. https:\/\/doi.org\/10.14309\/crj.0000000000001305","DOI":"10.14309\/crj.0000000000001305"},{"key":"4050_CR40","doi-asserted-by":"publisher","first-page":"omae043","DOI":"10.1093\/omcr\/omae043","volume":"5","author":"AA Abufara","year":"2024","unstructured":"Abufara AA, Alsahouri MI, Alsalah QA, Arafat H, Hammouri AG, Aqeel BA (2024) Spontaneous tumor lysis syndrome in an adult with alveolar rhabdomyosarcoma: a challenging diagnosis. Oxf Med Case Reports 5:omae043. https:\/\/doi.org\/10.1093\/omcr\/omae043","journal-title":"Oxf Med Case Reports"},{"key":"4050_CR41","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s12185-024-03752-w","volume":"6","author":"Y Toda","year":"2024","unstructured":"Toda Y, Ashizawa M, Murahashi R et al (2024) Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era. Int J Hematol 6:660\u2013666. https:\/\/doi.org\/10.1007\/s12185-024-03752-w","journal-title":"Int J Hematol"},{"key":"4050_CR42","doi-asserted-by":"publisher","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A on behalf of the TLS Expert Panel (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 4:578\u2013586. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08143.x","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"4050_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.11575","volume":"93","author":"P Montesinos","year":"2008","unstructured":"Montesinos P, Lorenzo I, Mart\u00edn G et al (2008) Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive mode. Haematologica 93:67\u201374. https:\/\/doi.org\/10.3324\/haematol.11575","journal-title":"Haematologica"},{"key":"4050_CR44","doi-asserted-by":"publisher","first-page":"102603","DOI":"10.1016\/j.ctrv.2023.102603","volume":"120","author":"AJ Perissinotti","year":"2023","unstructured":"Perissinotti AJ, Bishop MR, Bubalo J et al (2023) Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel. Cancer Treat Rev 120:102603. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102603","journal-title":"Cancer Treat Rev"},{"key":"4050_CR45","doi-asserted-by":"publisher","unstructured":"Jones GL, Will A, Jackson GH, Webb NJA, Rule S on behalf of British Committee for Standards in Haematology (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661\u201371. https:\/\/doi.org\/10.1111\/bjh.13403","DOI":"10.1111\/bjh.13403"},{"key":"4050_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13613-022-00990-1","volume":"12","author":"M Abdel-Nabey","year":"2022","unstructured":"Abdel-Nabey M, Chaba A, Serre J et al (2022) Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann Intensive Care 12:15. https:\/\/doi.org\/10.1186\/s13613-022-00990-1","journal-title":"Ann Intensive Care"},{"key":"4050_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/10428190903456959","volume":"51","author":"M Darmon","year":"2010","unstructured":"Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E (2010) Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 51:221\u2013227. https:\/\/doi.org\/10.3109\/10428190903456959","journal-title":"Leuk Lymphoma"},{"key":"4050_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3816\/CLM.2008.n.003","volume":"8","author":"S Candrilli","year":"2008","unstructured":"Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS (2008) A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 8:44\u201351. https:\/\/doi.org\/10.3816\/CLM.2008.n.003","journal-title":"Clin Lymphoma Myeloma"},{"key":"4050_CR49","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364:1844\u20131854. https:\/\/doi.org\/10.1056\/NEJMra0904569","journal-title":"N Engl J Med"},{"key":"4050_CR50","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.2215\/CJN.0000000000000331","volume":"18","author":"A Joseph","year":"2023","unstructured":"Joseph A, Zafrani L (2023) How I treat tumor lysis syndrome. Clin J Am Soc Nephrol 18:1634\u20131636. https:\/\/doi.org\/10.2215\/CJN.0000000000000331","journal-title":"Clin J Am Soc Nephrol"},{"key":"4050_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2399369319837212","volume":"3","author":"K Sury","year":"2019","unstructured":"Sury K (2019) Update on the prevention and treatment of tumor lysis syndrome. J Onco-Nephrol 3:19\u201330. https:\/\/doi.org\/10.1177\/2399369319837212","journal-title":"J Onco-Nephrol"},{"key":"4050_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.1965.03090010007001","volume":"193","author":"IH Krakoff","year":"1965","unstructured":"Krakoff IH, Meyer RL (1965) Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 193:1\u20136. https:\/\/doi.org\/10.1001\/jama.1965.03090010007001","journal-title":"JAMA"},{"key":"4050_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM196603032740902","volume":"274","author":"RC DeConti","year":"1966","unstructured":"DeConti RC, Calabresi P (1966) Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 274:481\u2013486. https:\/\/doi.org\/10.1056\/NEJM196603032740902","journal-title":"N Engl J Med"},{"key":"4050_CR54","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1007\/s00467-024-06413-6","volume":"39","author":"S Goswami","year":"2024","unstructured":"Goswami S, Hanson AE, Rajadhyaksha E, Dangle PP, Schwaderer AL (2024) Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series. Pediatr Nephrol 39:3217\u20133219. https:\/\/doi.org\/10.1007\/s00467-024-06413-6","journal-title":"Pediatr Nephrol"},{"key":"4050_CR55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2125.1998.00719.x","volume":"45","author":"HL McLeod","year":"1998","unstructured":"McLeod HL (1998) Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 45:539\u2013544. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00719.x","journal-title":"Br J Clin Pharmacol"},{"key":"4050_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00043426-199605000-00009","volume":"18","author":"CW Keuzenkamp-Jansen","year":"1996","unstructured":"Keuzenkamp-Jansen CW, DeAbreu RA, B\u00f6kkerink JP, Lambooy MA, Trijbels JM (1996) Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 18:145\u2013150. https:\/\/doi.org\/10.1097\/00043426-199605000-00009","journal-title":"J Pediatr Hematol Oncol"},{"key":"4050_CR57","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","volume":"36","author":"SN Ramasamy","year":"2013","unstructured":"Ramasamy SN, Korb-Wells CS, Kannangara DRW et al (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950\u20132012. Drug Saf 36:953\u2013980. https:\/\/doi.org\/10.1007\/s40264-013-0084-0","journal-title":"Drug Saf"},{"key":"4050_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/jcpt.12839","volume":"44","author":"I Bellos","year":"2019","unstructured":"Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V (2019) Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 44:525\u2013533. https:\/\/doi.org\/10.1111\/jcpt.12839","journal-title":"J Clin Pharm Ther"},{"key":"4050_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40360-023-00723-5","volume":"24","author":"H Xie","year":"2023","unstructured":"Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC (2023) Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. BMC Pharmacol and Toxicol 24:79. https:\/\/doi.org\/10.1186\/s40360-023-00723-5","journal-title":"BMC Pharmacol and Toxicol"},{"key":"4050_CR60","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","volume":"26","author":"M Spina","year":"2015","unstructured":"Spina M, Nagy Z, Jm R et al (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26:2155\u20132161. https:\/\/doi.org\/10.1093\/annonc\/mdv317","journal-title":"Ann Oncol"},{"key":"4050_CR61","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.9332-22","volume":"61","author":"S Ito","year":"2022","unstructured":"Ito S, Fujiwara SI, Yoshizawa T et al (2022) Urine xanthine crystals in hematologic malignancies with tumor lysis syndrome. Intern Med 61:3271\u20133275. https:\/\/doi.org\/10.2169\/internalmedicine.9332-22","journal-title":"Intern Med"},{"key":"4050_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cpt.2023.07.001","volume":"1","author":"K Mahfooz","year":"2023","unstructured":"Mahfooz K, Sohail H, Gvajaia A et al (2023) Rasburicase in treating tumor lysis syndrome: an umbrella review. Rev Cancer Pathog Ther 1:262\u2013271. https:\/\/doi.org\/10.1016\/j.cpt.2023.07.001","journal-title":"Rev Cancer Pathog Ther"},{"key":"4050_CR63","doi-asserted-by":"publisher","unstructured":"Ando Y, Nishiyama H, Shimodaira H, et al (2023) Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28:1315\u20131332. https:\/\/doi.org\/10.1007\/s10147-023-02382-2","DOI":"10.1007\/s10147-023-02382-2"},{"key":"4050_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ajh.23182","volume":"88","author":"MB Sonbol","year":"2013","unstructured":"Sonbol MB, Yadav H, Vaidya R, Rana V, Witzig TE (2013) Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol 88:152\u2013154. https:\/\/doi.org\/10.1002\/ajh.23182","journal-title":"Am J Hematol"},{"key":"4050_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/clpt.2014.97","volume":"96","author":"MV Relling","year":"2014","unstructured":"Relling MV, McDonagh EM, Chang T et al (2014) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 96:169\u2013174. https:\/\/doi.org\/10.1038\/clpt.2014.97","journal-title":"Clin Pharmacol Ther"},{"key":"4050_CR66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen KC, Champlain AH, Cotliaret JA et al (2015) Risk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) project. Drug Saf 38:183\u2013187. https:\/\/doi.org\/10.1007\/s40264-014-0255-7","journal-title":"Drug Saf"},{"key":"4050_CR67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"CH Pui","year":"2001","unstructured":"Pui CH, Mahmoud HH, Wiley JM et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.697","journal-title":"J Clin Oncol"},{"key":"4050_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.leu.2403566","volume":"19","author":"S Jeha","year":"2005","unstructured":"Jeha S, Kantarjian H, Irwin D et al (2005) Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 19:34. https:\/\/doi.org\/10.1038\/sj.leu.2403566","journal-title":"Leukemia"},{"key":"4050_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2013.02.378","volume":"62","author":"MA Lopez-Olivo","year":"2013","unstructured":"Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A (2013) Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 62:481\u2013492. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.378","journal-title":"Am J Kidney Dis"},{"key":"4050_CR70","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.1002\/14651858.CD006945.pub4","volume":"3","author":"DKL Cheuk","year":"2017","unstructured":"Cheuk DKL, Chiang AKS, Chan GCF, Ha SY (2017) Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev 3:6945. https:\/\/doi.org\/10.1002\/14651858.CD006945.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"4050_CR71","unstructured":"U.S. Food and Drug Administration (2024) Drug approvals and database. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103946. Accessed 7 June 2024"},{"key":"4050_CR72","doi-asserted-by":"publisher","first-page":"107815522412532","DOI":"10.1177\/10781552241253214","volume":"25","author":"A Kamel","year":"2024","unstructured":"Kamel A, Sanders M, Dyk H, Hamilton T (2024) A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system. J Oncol Pharm Practice 25:10781552241253214. https:\/\/doi.org\/10.1177\/10781552241253214","journal-title":"J Oncol Pharm Practice"},{"key":"4050_CR73","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.clml.2021.08.009","volume":"22","author":"S Yaman","year":"2022","unstructured":"Yaman S, Ba\u015fc\u0131 S, Turan G et al (2022) Single-dose rasburicase might be adequate to overcome tumor lysis syndrome in hematological malignancies. Clin Lymphoma Myeloma Leuk 22:e71\u2013e76. https:\/\/doi.org\/10.1016\/j.clml.2021.08.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4050_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/jcpt.12479","volume":"42","author":"X Yu","year":"2017","unstructured":"Yu X, Liu L, Nie X et al (2017) The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J Clin Pharm Ther 42:18\u201326. https:\/\/doi.org\/10.1111\/jcpt.12479","journal-title":"J Clin Pharm Ther"},{"key":"4050_CR75","doi-asserted-by":"publisher","first-page":"e68664","DOI":"10.7759\/cureus.68664","volume":"16","author":"S Bakhsh","year":"2024","unstructured":"Bakhsh S, Khan MA, Alshamrani M et al (2024) Effectiveness of a single fixed dose of 3 mg rasburicase for the prevention and management of hyperuricemia in tumor lysis syndrome in adults with cancer. Cureus 16:e68664. https:\/\/doi.org\/10.7759\/cureus.68664","journal-title":"Cureus"},{"key":"4050_CR76","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/10781552231190005","volume":"30","author":"S Gilmore","year":"2024","unstructured":"Gilmore S, Carroll M, Koselke E, Hough S (2024) Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices. J Oncol Pharm Pract 30:867\u2013872. https:\/\/doi.org\/10.1177\/10781552231190005","journal-title":"J Oncol Pharm Pract"},{"key":"4050_CR77","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/20009666.2020.1761185","volume":"10","author":"I Puri","year":"2020","unstructured":"Puri I, Sharma S, Gunturu KS, Ahmed AA (2020) Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect 10:269\u2013272. https:\/\/doi.org\/10.1080\/20009666.2020.1761185","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"4050_CR78","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11739-019-02217-x","volume":"15","author":"G Regolisti","year":"2020","unstructured":"Regolisti G, Maggiore U, Greco P et al (2020) Electrocardiographic T wave alterations and prediction of hyperkalemia in patients with acute kidney injury. Intern Emerg Med 15:463\u2013472. https:\/\/doi.org\/10.1007\/s11739-019-02217-x","journal-title":"Intern Emerg Med"},{"key":"4050_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2025.16.7.9","volume":"16","author":"K Byar","year":"2025","unstructured":"Byar K, Anderson A (2025) An overview of the management of electrolyte emergencies and imbalances in cancer patients. J Adv Pract Oncol 16:1\u201315. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.9","journal-title":"J Adv Pract Oncol"},{"key":"4050_CR80","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.3390\/jcm13247572","volume":"13","author":"A Duminuco","year":"2024","unstructured":"Duminuco A, Del Fabro V, De Luca P et al (2024) Emergencies in hematology: why, when and how I treat? J Clin Med 13:7572. https:\/\/doi.org\/10.3390\/jcm13247572","journal-title":"J Clin Med"},{"key":"4050_CR81","doi-asserted-by":"publisher","unstructured":"Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S (2019) Electrolyte disorders in cancer patients: a systematic review. J Cancer Metastasis Treat 5:79. https:\/\/doi.org\/10.20517\/2394-4722.2019.008","DOI":"10.20517\/2394-4722.2019.008"},{"key":"4050_CR82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/joa3.12482","volume":"37","author":"K Gangani","year":"2021","unstructured":"Gangani K, Fong HK, Faisaluddin M et al (2021) Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: a nationwide inpatient analysis. J Arrhythm 37:121\u2013127. https:\/\/doi.org\/10.1002\/joa3.12482","journal-title":"J Arrhythm"},{"key":"4050_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OAEM.S73684","volume":"7","author":"SA Namendys-Silva","year":"2015","unstructured":"Namendys-Silva SA, Arredondo-Armenta JM, Plata-Menchaca EP et al (2015) Tumor lysis syndrome in the emergency department: challenges and solutions. Open Access Emerg Med 7:39\u201344. https:\/\/doi.org\/10.2147\/OAEM.S73684","journal-title":"Open Access Emerg Med"},{"key":"4050_CR84","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40620-019-00648-5","volume":"32","author":"V Pistolesi","year":"2019","unstructured":"Pistolesi V, Zeppilli L, Fiaccadori E, Regolisti G, Tritapepe L, Morabito S (2019) Hypophosphatemia in critically ill patients with acute kidney injury on renal replacement therapies. J Nephrol 32:895\u2013908. https:\/\/doi.org\/10.1007\/s40620-019-00648-5","journal-title":"J Nephrol"},{"key":"4050_CR85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000082016","volume":"23","author":"R Ratanarat","year":"2005","unstructured":"Ratanarat R, Brendolan A, Volker G et al (2005) Phosphate kinetics during different dialysis modalities. Blood Purif 23:83\u201390. https:\/\/doi.org\/10.1159\/000082016","journal-title":"Blood Purif"},{"key":"4050_CR86","doi-asserted-by":"publisher","unstructured":"VA\/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O\u2019Connor TZ et al (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0802639","DOI":"10.1056\/NEJMoa0802639"},{"key":"4050_CR87","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","volume":"361","author":"R Bellomo","year":"2009","unstructured":"RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L et al (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627\u20131638. https:\/\/doi.org\/10.1056\/NEJMoa0902413","journal-title":"N Engl J Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-04050-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:03:30Z","timestamp":1764684210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-04050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4050"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-04050-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of article formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}